Effect of continuing the use of renin–angiotensin system inhibitors on mortality in patients hospitalized for coronavirus disease 2019: a systematic review, meta-analysis, and meta-regression analysis

Abstract

Background The effect of angiotensin-converting enzyme inhibitors (ACEIs)/angiotensin receptor blockers (ARBs) on mortality was preliminarily explored through the comparison of ACEIs/ARBs with non-ACEIs/ARBs in patients with coronavirus disease 2019 (COVID-19). Reaching a conclusion on whether previous ACEI/ARB treatment should be continued in view of the different ACE2 levels in the comparison groups was not unimpeachable. Therefore, this study aimed to further elucidate the effect of ACEI/ARB continuation on hospital mortality, intensive care unit (ICU) admission, and invasive mechanical ventilation (IMV) in the same patient population. Methods We searched PubMed, the Cochrane Library, Ovid, and Embase for relevant articles published between December 1, 2019 and April 30, 2022. Continuation of ACEI/ARB use after hospitalization due to COVID-19 was considered as an exposure and discontinuation of ACEI/ARB considered as a control. The primary outcome was hospital mortality, and the secondary outcomes included 30-day mortality, rate of ICU admission, IMV, and other clinical outcomes. Results Seven observational studies and four randomized controlled trials involving 2823 patients were included. The pooled hospital mortality in the continuation group (13.04%, 158/1212) was significantly lower than that (22.15%, 278/1255) in the discontinuation group (risk ratio [RR] = 0.45; 95% confidence interval [CI], 0.28–0.72; P = 0.001). Continuation of ACEI/ARB use was associated with lower rates of ICU admission (10.5% versus 16.2%, RR = 0.63; 95% CI 0.5–0.79; P < 0.0001) and IMV (8.2% versus 12.5%, RR = 0.62; 95% CI 0.46–0.83, P = 0.001). Nevertheless, the effect was mainly demonstrated in the observational study subgroup (P < 0.05). Continuing ACEI/ARB had no significant effect on 30-day mortality (P = 0.34), acute myocardial infarction (P = 0.08), heart failure (P = 0.82), and acute kidney injury after hospitalization (P = 0.98). Conclusion Previous ACEI/ARB treatment could be continued since it was associated with lower hospital deaths, ICU admission, and IMV in patients with COVID-19, although the benefits of continuing use were mainly shown in observational studies. More evidence from multicenter RCTs are still needed to increase the robustness of the data. Trial registration PROSPERO (CRD42022341169). Registered 27 June 2022

COVID-19 and the Use of Angiotensin II Receptor Blockers in Older Chronic Hypertensive Patients: Systematic Review and Meta-Analysis

“…Heart congestive failure and atrial fibrillation can be an adverse evolution in hypertensive patients, but actually, in the COVID era, hypertensive patients cannot be associated ACEI/ARAII use [ 56 , 57 ]. Recent studies have found that pre-treatment with ACEI/ARAII could be continued, as it was associated with lower hospital mortality, ICU admission and IMV in patients with COVID-19 [ 58 ]. For this reason, this medication should not be discontinued, especially ARAIIs [ 59 , 60 , 61 ].…”

Prognostic Factors Associated with Acute Heart Failure in Patients Admitted for COVID-19: Analysis of the SEMI-COVID-19 Registry

“…Although regular treatment with ACE inhibitors appears to be a factor associated with the development of HF, in this case, it may be acting as a confounding factor because it is a common treatment for patients with previous HF, nephropathy, or hypertension, which are risk factors for HF. This fact observed with the ACE inhibitors can also be transferred to other treatments commonly used in HF and cardiovascular disease, such as statins or anticoagulant drugs [21]. Casas Rojo et al showed a protective role of ACEI/ARA2 and statins [14].…”

A susceptibilidade de pacientes hipertensos contraírem o COVID-19 e desenvolver a forma grave da doença

“…A AT2 tem uma grande expressão na vida uterina fetal reduzindo sua função decorrer da idade do paciente, e se comparado um adulto apresenta uma relação de 1,9 receptores de AT1 em relação a AT2, já o AT1 ao se ligar a Angiotensina II estimula a produção de vasopressina, aumenta o tônus simpático liberando catecolaminas, em especial a noradrenalina (Liu, et al, 2023). Já nas glândulas suprarrenais, a estimulação de catecolaminas também é expressada, aumentando a liberação de adrenalina que acabam causando uma vasoconstrição nos vasos sanguíneos de indivíduos com HAS crônica (Tanzadehpanah, et al,2023).…”